Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc. Sanofi announced today that it has withdrawn and refiled its Premerger Notification and Report Form…
Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from several COVID-19 clinical and real-world evidence studies being presented at the 33rd European Congress of Clinical Microbiology &…
Bristol Myers Squibb Submits Application for Abecma®, a CAR T Cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least Two Prior Therapies Bristol-Myers Squibb K.K. announced today that the company has submitted the supplemental…
Roche data highlights the strength of the ophthalmology portfolio and commitment to advancing eye care at ARVO 2023 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data for its approved and investigational medicines will be highlighted in 30…
AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST) Amgen (NASDAQ:AMGN) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the District of New Jersey in a patent infringement lawsuit against Sandoz Inc. (“Sandoz”) and Zydus Pharmaceuticals…
Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023. Lilly will also conduct a conference call that day with the investment community…
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS WIRE)– Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and…
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn’s Disease AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ® (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance…
AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year AbbVie today announced that the AbbVie Cystic Fibrosis (CF) Scholarship, a program that is making a difference in the lives of…
CoolSculpting® Elite Announces First Ever CoolMonth LAUNCHES THE COOLEST PROMOTION WITH A BUY 4, GET 4 DEAL AT PARTICIPATING PROVIDERS TO SUPPORT YOUR BODY CONTOURING JOURNEY IRVINE, Calif., April 3, 2023 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and the…